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Abstract
We compared the rate and extent of anidulafungin’s and ﬂuco-
nazole’s activity in neutropenic and non-neutropenic mice with
Candida albicans invasive candidiasis. In immunocompetent mice,
anidulafungin signiﬁcantly improved survival vs. controls and
ﬂuconazole, and signiﬁcant reductions in (1 ﬁ 3)-b-D-glucan and
fungal burden were observed. In neutropenic animals, the high-
est doses of anidulafungin (5 mg/kg) and ﬂuconazole (10 mg/kg)
also improved survival and reduced fungal burden. However,
there were no differences in survival between these antifungals
as anidulafungin’s activity was attenuated in this model. These
results demonstrate that the extent of anidulafungin in vivo efﬁ-
cacy may be dependent on host immune status.
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Anidulafungin has been shown to be non-inferior to ﬂucona-
zole for invasive candidiasis in a prospective, randomized
clinical trial [1]. In the secondary analysis of overall clinical
and microbiological responses by infecting pathogen, anidula-
fungin was superior against infections caused by C. albicans.
However, only a small percentage of patients were neu-
tropenic at the time of enrollment. In vivo models of dissemi-
nated candidiasis have also demonstrated signiﬁcant activity
for anidulafungin against C. albicans, although these have
solely utilized neutropenic animals [2–4]. Thus, a true com-
parison of the in vivo efﬁcacy of anidulafungin between neu-
tropenic and non-neutropenic hosts is lacking. Our objective
was to compare the in vivo rate and extent of activity of
anidulafungin against C. albicans in both neutropenic and
non-neutropenic models of invasive candidiasis. Outcome
measures were survival and reductions in fungal burden and
(1 ﬁ 3)-b-D-glucan concentrations. We hypothesized that
anidulafungin therapy would result in rapid and extensive in
vivo activity regardless of immune status.
Outbred ICR mice (Harlan), weighing between 22 and 25 g,
were used in all experiments. In the neutropenic model, ani-
mals were administered intravenous 5-ﬂuorouracil 150 mg/kg
1 day prior to inoculation (<100 neutrophils/mm3 for
>10 days) [5]. On day 0, animals were infected intravenously
with C. albicans ATCC 90028 (c. 1 · 106 cells/mouse; anidula-
fungin and ﬂuconazole MICs of 0.03 and 0.5 mg/L, respec-
tively) [6]. This study was approved by the Institutional
Animal Care and Use Committee at the UT Health Science
Center San Antonio. Mice were then randomly placed into
ﬁve groups: untreated controls, anidulafungin 1 or 5 mg/kg/
day IV, and ﬂuconazole 5 or 10 mg/kg/day IV. The lowest
doses are similar to the reported ED50s of each agent and
result in clinically relevant concentrations [2,7–10]. Therapy
began 24 h later and continued through to day 7. In the sur-
vival arm, mice were monitored off therapy until day 21. Any
animal that appeared moribund was euthanized, with death
recorded as occurring the next day. In the fungal burden arm,
kidneys and serum were collected 1 day after inoculation
prior to antifungal therapy, and on days 4–7. Kidneys were
also collected on day 8, 1 day after treatment stopped. Kid-
neys were weighed and homogenized in sterile saline. Serial
dilutions were prepared and plated, and following 24 h of
incubation at 37C, fungal burden (CFU/g) was determined.
Serum (1 ﬁ 3)-b-D-glucan concentrations were measured
using a commercially available kit (Fungitell, Associates of
Cape Cod, East Falmouth, MA, USA). Survival was plotted by
Kaplan–Meier analysis, and differences in median and per cent
survival were analysed by the log-rank test and Fischer’s exact
test, respectively. Differences in (1 ﬁ 3)-b-D-glucan and fun-
gal burden were assessed by ANOVA with Tukey’s post-test.
In non-neutropenic mice, the median survival was signiﬁ-
cantly longer for anidulafungin (>21 days for both doses)
and ﬂuconazole (16.5 and 18 days at 5 and 10 mg/kg,
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respectively) compared with untreated controls (6.5 days,
p <0.01; Fig. 1). Anidulafungin also signiﬁcantly improved the
survival rate (85.7% and 90.5% at 1 and 5 mg/kg, respec-
tively) vs. controls (5%, p <0.0001) and ﬂuconazole (40% and
26% at 5 and 10 mg/kg, respectively; p <0.01). In neutropenic
mice, although treatment with anidulafungin signiﬁcantly
improved both the median and per cent survival (8 days and
42.9% for each dose, respectively) vs. controls (5 days and
0%; p <0.01), these values were signiﬁcantly less than those
observed in the non-neutropenic model. In contrast, survival
FIG. 1. Survival in neutropenic (clear symbols) and non-neutropenic (black symbols) mice infected intravenously with Candida albicans ATCC
90028. Antifungal therapy began 24 h post-inoculation. Groups consisted of untreated controls (n = 23 and 20 neutropenic and non-neutropenic
mice, respectively), anidulafungin 1 mg/kg/day (circles; n = 21 mice per model) and 5 mg/kg/day (diamonds; n = 21 mice per model), or ﬂuconaz-
ole 5 mg/kg/day (circles; n = 20 mice per model) and 10 mg/kg/day (diamonds; n = 19 mice per model). Both antifungals were administered
intravenously for 7 days and mice were followed off therapy until day 21 post-inoculation. Median survival was signiﬁcantly longer for both doses
of anidulafungin and ﬂuconazole compared with controls in neutropenic and non-neutropenic mice.
FIG. 2. Changes in fungal burden within kidney tissue and serum (1 ﬁ 3)-b-D-glucan over time in neutropenic (n = 5 per group) and non-neu-
tropenic (n = 10 per group) mice infected intravenously with C. albicans ATCC 90028. Groups consisted of untreated controls, anidulafungin 1
and 5 mg/kg/day, or ﬂuconazole 5 and 10 mg/kg/day. Mean values and standard error of the mean are presented. For the fungal burden data,
white bars depict data from the neutropenic model and grey bars the data from the non-neutropenic model. For the (1 ﬁ 3)-b-D-glucan data,
clear symbols and dotted lines demonstrate data from the neutropenic model and black symbols and solid lines data from the non-neutropenic
model. *p-value <0.05 vs. untreated controls.
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did not signiﬁcantly differ between neutropenic and non-neu-
tropenic mice treated with ﬂuconazole. The survival arms
were repeated on separate occasions, and there were no sig-
niﬁcant differences between the repeat experiments for both
the neutropenic and non-neutropenic models.
Anidulafungin 5 mg/kg had the most rapid activity, with
signiﬁcant reductions in fungal burden occurring by day 4 in
both neutropenic and non-neutropenic mice (3.20 and 2.72
log10 CFU/g, respectively) vs. controls (7.30 and 5.11
log10 CFU/g, respectively; p <0.001) (Fig. 2). Although ﬂuco-
nazole also signiﬁcantly reduced fungal burden, this was
delayed until day 6, and the reductions observed with anidu-
lafungin 5 mg/kg were greater than those for both ﬂuconaz-
ole doses. Signiﬁcant reductions in fungal burden were also
observed with anidulafungin 1 mg/kg in immunocompetent
animals; however, no differences were found in neutropenic
mice. Fungal burden was also evaluated on day 8. Although
not statistically signiﬁcant, there was a trend towards a
greater number of sterile samples in non-neutropenic vs.
neutropenic mice treated with anidulafungin 5 mg/kg [17 of
23 (74%) vs. nine of 17 (53%) of samples; p 0.09]. Neither
anidulafungin 1 mg/kg nor either of the ﬂuconazole doses
resulted in complete organism eradication from the kidneys
of any animal.
A downward trend in (1 ﬁ 3)-b-D-glucan over time also
occurred with antifungal therapy in immunocompetent mice.
By day 7 (1 ﬁ 3)-b-D-glucan concentrations were signiﬁ-
cantly lower for each agent compared with controls. Consis-
tent with the fungal burden data, anidulafungin 5 mg/kg did
lead to signiﬁcantly lower (1 ﬁ 3)-b-D-glucan concentrations
in both models, which were evident by day 4. Despite these
signiﬁcant reductions, (1 ﬁ 3)-b-D-glucan levels measured in
neutropenic mice remained well above the threshold for
positivity (80 pg/mL).
Our fungal burden and (1 ﬁ 3)-b-D-glucan data are con-
sistent with previous studies of anidulafungin’s in vivo efﬁcacy
[2,3]. However, we also observed a difference in survival
between the neutropenic and non-neutropenic animals.
While the rate and extent of anidulafungin’s activity as mea-
sured by fungal burden and (1 ﬁ 3)-b-D-glucan appeared to
be similar between the models, the survival advantage was
attenuated in neutropenic mice. Worse response rates have
been reported for caspofungin in the setting of neutropenia,
both clinically and in animal models [11,12]. One potential
explanation may be regrowth of the infecting organism once
therapy stopped in the absence of neutrophils. It is known
that the echinocandins can act in conjunction with the innate
immune response by unmasking b-glucans and exposing this
pathogen-associated molecular pattern to dectin-1 on macro-
phages, neutrophils and dendritic cells [13–17]. Thus, once
treatment stopped, growth of surviving Candida cells may
have continued in neutropenic mice. Additional work is nec-
essary to further explore potential differences in efﬁcacy for
anidulafungin in relation to host immune status.
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